Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma.

Zhang Y, Jin B, Shao M, Dong Y, Lou Y, Huang A, Han B.

Tumour Biol. 2014 May;35(5):4921-8. doi: 10.1007/s13277-014-1646-1. Epub 2014 Jan 24.

PMID:
24459065
2.

Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.

Li H, Wang Y, Su F, Li J, Gong P.

Int J Clin Exp Pathol. 2015 May 1;8(5):5577-83. eCollection 2015.

4.

Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.

Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N.

J Thorac Oncol. 2013 Jul;8(7):892-8. doi: 10.1097/JTO.0b013e31828c3929.

5.

Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.

Pan JB, Hou YH, Zhang GJ.

Asian Pac J Cancer Prev. 2013;14(2):695-700.

6.

Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy.

Choi CM, Kim MY, Lee JC, Kim HJ.

Radiology. 2014 Feb;270(2):574-82. doi: 10.1148/radiol.13121824. Epub 2013 Oct 28.

PMID:
24086072
7.

Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.

Ko KH, Hsu HH, Huang TW, Gao HW, Shen DH, Chang WC, Hsu YC, Chang TH, Chu CM, Ho CL, Chang H.

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1889-97. doi: 10.1007/s00259-014-2802-y. Epub 2014 May 23. Erratum in: Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1989-90.

PMID:
24852187
8.

Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung.

Nose N, Uramoto H, Iwata T, Hanagiri T, Yasumoto K.

Lung Cancer. 2011 Mar;71(3):350-5. doi: 10.1016/j.lungcan.2010.06.009. Epub 2010 Jul 8.

PMID:
20615575
9.

Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas.

Shoji F, Yoshino I, Yano T, Kometani T, Ohba T, Kouso H, Takenaka T, Miura N, Okazaki H, Maehara Y.

Cancer. 2007 Dec 15;110(12):2793-8.

10.

[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].

Zhao LD, Li JL, Wang Y, Wang B, Wang HY, Hao XZ, Cui CX, Zhang XR, Shi YK.

Zhonghua Zhong Liu Za Zhi. 2011 Mar;33(3):217-21. Chinese.

PMID:
21575523
11.

[Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKI in advanced non-small cell lung cancer harboring EGFR mutations].

Jin B, Zhang Y, Zhang X, Li R, Lou Y, Niu Y, Huang A, Han B.

Zhonghua Yi Xue Za Zhi. 2014 Aug 13;94(30):2327-31. Chinese.

PMID:
25399971
12.

[Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations].

Zhu X, Liang L, Liu C, Yin W, Chen S, Cao B.

Zhongguo Fei Ai Za Zhi. 2014 Feb;17(2):155-62. doi: 10.3779/j.issn.1009-3419.2014.02.15. Chinese.

13.

Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients.

Shan L, Wang Z, Guo L, Sun H, Qiu T, Ling Y, Li W, Li L, Liu X, Zheng B, Lu N, Ying J.

Lung Cancer. 2015 Sep;89(3):337-42. doi: 10.1016/j.lungcan.2015.06.008. Epub 2015 Jun 19.

PMID:
26141217
15.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

16.

Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.

Krawczyk P, Kowalski DM, Krawczyk KW, Szczyrek M, Mlak R, Rolski A, Szudy A, Kieszko R, Winiarczyk K, Milanowski J, Krzakowski M.

Oncol Rep. 2013 Sep;30(3):1463-72. doi: 10.3892/or.2013.2553. Epub 2013 Jun 19.

PMID:
23783797
17.

Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.

Kim HR, Cho BC, Shim HS, Lim SM, Kim SK, Chang J, Kim DJ, Kim JH.

Lung Cancer. 2014 Mar;83(3):374-82. doi: 10.1016/j.lungcan.2013.12.011. Epub 2014 Jan 3.

PMID:
24468202
18.

Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.

Tseng YH, Tseng YC, Lin YH, Lee YC, Perng RP, Whang-Peng J, Chen YM.

Oncologist. 2015 Jul;20(7):758-66. doi: 10.1634/theoncologist.2014-0352. Epub 2015 Jun 8.

19.
20.

Analysis of CEA expression and EGFR mutation status in non-small cell lung cancers.

Yang ZM, Ding XP, Pen L, Mei L, Liu T.

Asian Pac J Cancer Prev. 2014;15(8):3451-5.

Items per page

Supplemental Content

Write to the Help Desk